The Senate Health, Education, Labor & Pensions (HELP) Committee convened a hearing with the Chief Executive Officer (CEO) of Novo Nordisk, Lars Jorgensen, to discuss the high prices for its diabetes and obesity medications, Ozempic and Wegovy. The Senators acknowledged the transformative nature of GLP-1 agonists, like Ozempic and Wegovy, in addressing the diabetes and obesity epidemic, but asserted that… (Slifer, September 24, 2024) #Drug Pricing, #Prescription Drugs